ArticleInvestigative ophthalmology & visual science2026
Integrin-Linked Kinase Suppression Reduces SPARC's Effect on Intraocular Pressure and Extracellular Matrix.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Purpose: The molecular pathway for increased outflow resistance in the trabecular meshwork (TM) remains unknown. Secreted protein, acidic and rich in cysteine (SPARC) has been shown to regulate intraocular pressure (IOP) correlating to extracellular matrix (ECM) alterations. In other tissues, SPARC binds integrin-linked kinase (ILK) and regulates ECM organization through signaling cascades. We hypothesized SPARC regulates ECM proteins partly through ILK in the TM. Methods: Adenovirus carrying cDNA of human SPARC (Ad.SPARC) was used to overexpress SPARC and a lentivirus carrying short-hairpin RNA (shRNA) targeting human ILK (shILK) was used to inhibit ILK in live mice, primary human TM cells, and perfused human cadaveric anterior segments. IOP was measured in mice and human anterior segments. Selected ECM proteins were analyzed by immunoblotting and immunostaining. Results: SPARC overexpression elevated IOP 1.87 ± 0.50 millimeters of mercury (mm Hg; P = 0.009, n = 15) in mice. Coinfection with ILK inhibition reduced IOP by 3.64 ± 0.57 mm Hg (P < 0.001, n = 15) and histologically reduced ECM proteins compared to SPARC overexpression. In human anterior segments, SPARC overexpression elevated IOP 2.10 ± 0.25-fold (P = 0.021, n = 4), whereas addition of shILK attenuated SPARC's effect and decreased IOP 0.61 ± 0.31-fold (P = 0.015, n = 4). In human TM cells, Ad.SPARC infection elevated levels of SPARC and laminin. Coinfection with shILK reduced levels of ILK, collagen I, collagen VI, and laminin. Conclusions: ILK inhibition attenuated the effects of SPARC overexpression on IOP and ECM proteins, suggesting ILK signaling may contribute to the pathway of SPARC-mediated regulation of ECM homeostasis in TM. Future studies evaluating the downstream transcription factors may provide an elucidated pathway for POAG pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.